Nature Biotechnology
\n (2026) Cite this article<\/p>\n
The development of cGAS\u2013STING (stimulator of interferon genes) agonists as mRNA vaccine adjuvants has been hampered by widespread STING expression and by the observation that codelivered STING agonists suppress antigen mRNA translation. Here, to address these challenges, we engineer synchronized STING (Syn-STING): a lipid nanoparticle (LNP) codelivering antigen mRNA, mRNA encoding full-length STING transmembrane protein and a bioorthogonal-like delayed-release STING activator, DMXAA. DMXAA release is controlled by a biodegradable linker, enabling localized mouse STING activation while avoiding systemic endogeneous human STING recognition. In humanized STING mouse models, we test human papillomavirus E7 and ovalbumin antigens with mouse STING or a human STING mutant engineered for DMXAA specificity. Intratumoral or subcutaneous LNPs are preferentially internalized by myeloid cells, preserving antigen expression fidelity, achieving localized STING activation in antigen-presenting cells and preventing systemic regulatory B cell differentiation and immunocyte apoptosis. The Syn-STING vaccine elicits robust adaptive responses and Th1-biased T cell immunity. It suppresses tumor growth and prolongs survival while exhibiting negligible anti-STING immunity.<\/p>\n
This is a preview of subscription content, access via your institution<\/p>\n
Access Nature and 54 other Nature Portfolio journals<\/p>\n
Get Nature+, our best-value online-access subscription<\/p>\n
Receive 12 print issues and online access<\/p>\n
Prices may be subject to local taxes which are calculated during checkout<\/p>\n
All data supporting the findings described in this paper are available in the article and its Supplementary Information. Source data are provided with this paper.<\/p>\n
Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases\u2014advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).<\/p>\n
Article\u00a0
\n CAS\u00a0
\n PubMed\u00a0<\/p>\n
Google Scholar\u00a0<\/p>\n
Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489\u2013500 (2024).<\/p>\n
Article\u00a0
\n PubMed\u00a0<\/p>\n
Google Scholar\u00a0<\/p>\n
Pulendran, B., Arunachalam, P. S. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).<\/p>\n
Article\u00a0
\n CAS\u00a0
\n PubMed\u00a0
\n PubMed Central\u00a0<\/p>\n
Google Scholar\u00a0<\/p>\n
Zhao, T. M. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).<\/p>\n